I’ll admit it. When I first saw the headline about tobacco plants producing five psychedelics at once, I thought someone had gotten into the lab supply a little too enthusiastically. But no. This is real, it’s published in Science Advances, and frankly, it’s one of the most elegant pieces of metabolic engineering I’ve seen in the psychedelic space.
Let me walk you through what happened, why it matters, and what it means for anyone who cares about the intersection of plants, brains, and medicine.
What the Researchers Did
A team led by Asaph Aharoni at the Weizmann Institute of Science in Israel started with a deceptively simple question: can we map the complete biosynthetic pathway for DMT in plants, and then use that knowledge to build something bigger?
They focused on two DMT-producing species, Psychotria viridis (the chacruna leaf used in ayahuasca) and Acacia acuminata (an Australian tree). After identifying the key enzymes responsible for converting tryptophan into DMT, they inserted those genes into Nicotiana benthamiana, a fast-growing tobacco relative that’s essentially the Swiss Army knife of plant biology labs.
But they didn’t stop at DMT. By combining genetic machinery from mushrooms (Psilocybe cubensis), the Sonoran Desert toad (Rhinella marina), and additional supporting enzymes from rice and cress, they got the tobacco plants to simultaneously produce five tryptamine psychedelics:
- DMT (from plants)
- Psilocin (from mushrooms)
- Psilocybin (from mushrooms)
- Bufotenin (from toads)
- 5-MeO-DMT (from toads)
Five compounds. Three kingdoms of life. One tobacco leaf.
Why a Neurobotanist Should Care
From a pharmacological standpoint, what makes this interesting isn’t the novelty factor, it’s the platform. All five of these compounds are tryptamine derivatives built from the same amino acid precursor, tryptophan. They share a core indole ring structure but diverge in their methylation patterns and receptor binding profiles. Psilocybin is a prodrug that the body converts to psilocin. 5-MeO-DMT hits 5-HT₁A receptors with a ferocity that distinguishes its phenomenology from classical 5-HT₂A agonists like psilocin and DMT. Bufotenin has historically been the odd duck of the group,debated for decades regarding whether it even crosses the blood-brain barrier effectively.
The point is: these aren’t interchangeable molecules. They have distinct pharmacodynamic profiles, different subjective effect signatures, and potentially different therapeutic windows. Having a single biological chassis that can produce all of them (and be tuned to produce modified analogs that don’t exist in nature) opens the door to structure-activity relationship studies that would be far more cumbersome with traditional synthetic chemistry or wild harvesting.
And that brings us to the bigger issue.
The Sourcing Problem Is Real
If you’ve spent any time in ethnobotanical or psychedelic research circles, you know the supply chain conversation is getting louder. Psilocybin mushrooms can be cultivated, sure, but the variability in alkaloid content between strains, flushes, and even individual fruiting bodies is a regulatory headache. DMT-containing plant species are being overharvested in parts of South America. And the Sonoran Desert toad (Incilius alvarius), the source of 5-MeO-DMT and bufotenin, is under genuine conservation pressure from people literally squeezing toads for their secretions.
We cannot build a therapeutic pipeline on the back of ecological exploitation. That’s not a philosophical position. It’s a practical one. Clinical trials require standardized, reproducible material. GMP-grade manufacturing demands consistency. You can’t submit a toad to the FDA.
This is where plant-based biosynthesis starts to look genuinely compelling. Tobacco is cheap to grow, well-characterized genetically, and produces abundant tryptophan. The yields in this study are still modest — lower than what you’d find in natural producers — but this is a proof of concept, not a production facility. The researchers showed they could improve output by tweaking a single amino acid in one of the pathway enzymes. That’s the kind of optimization that scales.
The Part That Really Got My Attention
Beyond the five natural compounds, the team also demonstrated they could produce modified versions, analogs that don’t occur in nature, by engineering mutant enzymes with altered substrate specificities. This is where things shift from “cool biotechnology” to “potential game-changer for drug discovery.”
One of the persistent challenges in psychedelic medicine is that the compounds we have were discovered by evolutionary accident, not rational drug design. Psilocybin works, but it also produces a 4-6 hour trip that requires clinical supervision. 5-MeO-DMT is profoundly potent but carries cardiovascular risks. What if you could systematically generate a library of structural analogs in a plant system and screen them for therapeutic efficacy versus side effect burden?
That’s not science fiction. That’s what this platform makes possible.
A Note of Caution
Let’s keep our feet on the ground for a moment. The gene expression in this study is transient, introduced via bacterial infiltration rather than stable genomic integration. The plants don’t pass these traits to their seeds. The concentrations are low. And there’s a long road between “we detected psilocybin in a tobacco leaf” and “here’s your GMP-certified, clinically validated supply chain.”
There are also legitimate questions about regulation. As the study’s lead author noted, permanently engineering these pathways into a heritable plant line raises obvious concerns about diversion and misuse. The transient expression system is partly a feature, not a bug, it keeps the genie at least partially in the bottle.
But the trajectory is clear. Whether the ultimate production platform ends up being engineered plants, yeast, or bacteria (and smart money says microbes will probably win the scale-up race), the fundamental insight here is biological: the enzymatic logic for making these compounds is modular, portable, and combinable across kingdoms of life.
The Bigger Picture
We’re living through a moment where the ancient relationship between humans and psychoactive plants is being re-examined through the lens of modern neuroscience, and now, synthetic biology. Indigenous peoples across the Amazon, Mesoamerica, and West Africa have known about these compounds for centuries or millennia. The pharmacology is catching up. The biotechnology is now catching up to the pharmacology.
For those of us who sit at the intersection of neuropharmacology and botany, this study is a reminder that plants aren’t just sources of drugs, they’re collaborators in understanding how molecules interact with nervous systems. The tryptophan-to-tryptamine pathway is ancient, conserved, and apparently flexible enough to be rewired across species boundaries with remarkable ease.
One tobacco plant. Five psychedelics. Three kingdoms. And a whole lot of questions worth pursuing.